Pages tagged “FDA”
-
ACS Presents: A Policy Panel on Rescheduling
On September 24, 2024, the Association of Cannabinoid Specialists hosted a paneled event surrounding the topic of policy and rescheduling, and what it means for patients and clinicians.
Written by Kelsey Engvik
September 24, 2024 -
ACS – MCRAA Joint Comments on FDA Proposed Research Guidelines
The Medical Cannabis Research Advocacy Alliance (MCRAA) appreciates the opportunity to provide comments in response to the US Food and Drug Administration (FDA)’s Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Draft Guidance for Industry; Availability 85 FR 44305 (July 22, 2020).
Written by Jordan Tishler
February 25, 2024 -
CBD RFI Response from Association of Cannabinoid Specialists
Recently ACS was asked to provide a response to the request for information from Congress with regard to regulation of CBD and derivatives. The full response is available below and in pdf form here.
Written by Jordan Tishler
August 22, 2023